Latest Conference Coverage

Eptinezumab Improves Consecutive Migraine-Free Days, Shortens Migraine Duration

These data on the preventive migraine treatment confirmed findings from previous studies, with eptinezumab not only reducing total migraine days, but elongating the duration of consecutive migraine-free days.

Epidiolex Has Safe, Consistent Profile Over Long-Term in Tuberous Sclerosis Complex

Treatment with CBD resulted in a significant number of patients with TSC reporting being “much” or “very much” improved on the Subject/Caregiver Global Impression of Change.

M. Scott Perry, MD: Clinical Experience With Fenfluramine in Dravet Syndrome

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed his experience with Zogenix’s investigational Dravet syndrome treatment in clinical trials and in the Expanded Access Program.

Optimizing Acute Migraine Care Improves Quality of Life and Reduces Disability

Data from the OVERCOME study of more than 20,000 respondents suggest that those whose acute migraine treatment was optimized according to the mTOQ had less disability and better quality of life.

Ofatumumab Displays Superiority to Teriflunomide in Relapsing MS

Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression compared to teriflunomide in relapsing multiple sclerosis.

M. Scott Perry, MD: Real-World Fenfluramine Data in Dravet Syndrome

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed the real-world data collected from the Expanded Access Program for fenfluramine (Fintepla; Zogenix) in patients with Dravet syndrome.

Rimegepant Shows Early Efficacy in Acute Migraine Treatment

Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose.

Real-World Dravet Syndrome Data Suggest Fenfluramine Provides Benefit

The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.

Post-Hoc Analysis Suggests Eptinezumab Effective for Migraine at Initial Dosing

Data confirmed the prior results of the PROMISE-1 and PROMISE-2 studies, indicating the preventive effect on migraine with eptinezumab begins as early as day 1 post-infusion.

BTK Inhibitor SAR442168 Meets Multiple Sclerosis End Points in Phase 2b

The drug's impact on neuroinflammation and neurodegeneration in the brain and spinal cord are currently being explored.

Siponimod Shows Long-Term Benefit for Secondary Progressive MS

Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.

Erenumab Improves Daily Functioning and Quality of Life

The Novartis agent showed significant reduction of migraine days in both the real-world TELESCOPE and PERISCOPE studies in patients with migraine.

Perampanel May Improve Insomnia in Patients With Epilepsy and Anxiety

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.

Mary Rensel, MD: Transitioning to Shared Medical Appointments

The director of Pediatric MS and Wellness programming at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine discussed the harsh realities of patients adopting a new treatment method.

Le Hua, MD: Siponimod in Secondary Progressive Multiple Sclerosis

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed what can currently be surmised about siponimod’s effect in treating patients with SPMS.

Le Hua, MD: Subanalysis of the EXPAND Study of Siponimod in SPMS

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.

Le Hua, MD: Considering Age in Multiple Sclerosis Treatment

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the need to take age into consideration when managing a patient with MS, and how the thinking about the disease and age has shifted.

Le Hua, MD: Disease Duration and Age in MS

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed the current thinking about the challenges of addressing multiple sclerosis in older patients.

Robert Glanzman, MD: Overview of CNM-Au8

The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.

Quick Access to EVT Centers for Acute Stroke Is Greatly Limited, Study Suggests

Data suggests that access to endovascular thrombectomy centers within 15 minutes is limited to less than one-fifth of the population, pointing to a need for improved access and bypass methodologies.

Mary Rensel, MD: Integrating Shared Medical Appointments in MS

The director of Pediatric MS and Wellness at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine describes her study on shared medical appointments and the intricacies of integrating them into the common care realm.

Carrie Hersh, DO, MSc: Measuring Progressive Multiple Sclerosis

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, discussed the challenges of current measurements and the need to adjust the reading of progressive MS.

Tanuja Chitnis, MD: Consequences of Incomplete Recovery in MS

The director of the Partners Pediatric MS Center at Massachusetts General Hospital for Children provided insight on the consequences of incomplete relapse recovery in multiple sclerosis.

Carrie Hersh, DO, MSc: Addressing Progressive Disease in MS

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, spoke to the importance of preventing progression in MS and treating the non-inflammatory aspects of the disease.

Augusto Miravalle, MD: How Cladribine Sets Itself Apart in MS

The associate professor in the department of neurology at the University of Colorado and neurologist at Advanced Neurology of Colorado discussed the advantages of cladribine and details of the ongoing CLICK-MS study.

Cladribine Effectively Reduces Risk of Secondary Progressive Multiple Sclerosis

Similar effects were observed for each proxy SMPS component when compared with placebo.

Endovascular Therapy Displays Similar Outcomes to Intravenous Thrombolysis

When performed by itself, endovascular therapy had greater rates of intracranial hemorrhage compared to a combination of both endovascular therapy and intravenous thrombolysis.

CNM-Au8 Improves Visual Acuity in Patients With MS With Optic Neuropathy

This included the first 34 participants from the VISIONARY-MS study, which is currently ongoing with the orally delivered suspension of clean-surfaced, faceted gold nanocrystals.

Cladribine Shows Durable Efficacy in Relapsing Multiple Sclerosis

Data from the CLARITY extension trial suggest that the durability of treatment with cladribine extended beyond 24 months in those with relapsing-remitting multiple sclerosis.

Incomplete Recovery From MS Relapse May Contribute to Long-Term Disability

Recovery status may be a useful tool to predict long-term outcomes in patients with relapsing forms of multiple sclerosis.